article thumbnail

Enhancing Patient Care and System Revenue: The Case for Onsite Specialty Pharmacies in 340B Hospitals

Proxsys Rx

Why a Specialty Pharmacy? Overview) As chronic illnesses become increasingly common in the United States, the number of specialty medications for managing these conditions has skyrocketed. Which is why, according to some online reports, nearly 80% of new drug introductions are now specialty medications. Better Incomes.

article thumbnail

Enhancing Patient Care and System Revenue: The Case for Onsite Specialty Pharmacies in 340B Hospitals

Proxsys Rx

Why a Specialty Pharmacy? Overview) As chronic illnesses become increasingly common in the United States, the number of specialty medications for managing these conditions has skyrocketed. Which is why, according to some online reports, nearly 80% of new drug introductions are now specialty medications. Better Incomes.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Enhancing Patient Care and System Revenue: The Case for Onsite Specialty Pharmacies in 340B Hospitals

Proxsys Rx

Why a Specialty Pharmacy? Overview) As chronic illnesses become increasingly common in the United States, the number of specialty medications for managing these conditions has skyrocketed. Which is why, according to some online reports, nearly 80% of new drug introductions are now specialty medications. Better Incomes.

article thumbnail

Informa Connect’s Compliance Congress for Specialty Products

Drug Channels

Up your compliance game at this important event serving the unique sector of Specialty Products, the 7th annual Virtual Compliance Congress for Specialty Products.

article thumbnail

Conference Connect: Determining the Future of Specialty Pharmacy

Pharmaceutical Commerce

Asembia’s AXS25 Summit—held annually at both the Wynn and Encore in Las Vegas, NV—brings together thousands of pharmaceutical industry executives in hopes of continuing the conversation surrounding specialty pharmacy.

article thumbnail

Pharmacists Reimagine Myeloma Care With Insights from ASCO

Pharmacy Times

This is progressing through a phase 3 trial and includes comparator arms with standard-of-care treatments like daratumumab, bortezomib (Velcade; Millennium/Takeda and Janssen Pharmaceutical Companies), and lenalidomide. 2 We’re still trying to figure out where these new treatments best fit.

article thumbnail

Understanding Recent Changes to 505(b)(2) Drugs and Reimbursement

Pharmacy Times

In 2022, based upon a complaint filed by a pharmaceutical company, CMS was asked to reevaluate the SSA section that establishes the J-code,” Soefje said. So, the pharmaceutical companies then pushed to get their 505(b)(2) drugs declared sole source,” Soefje said. “If This went into effect in January 2022.”